Central retinal vein occlusion occurring immediately after 2nd dose of mRNA SARS-CoV-2 vaccine

Bialasiewicz, A. A.; Farah-Diab, M. S.; Mebarki, H. T.

doi:10.1007/s10792-021-01971-2

Cited by 49 publications

(54 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two reports of central retinal vein occlusion (CRVO) have been made following vaccination against COVID-19. Bialasiewicz et al reported on a 50-year-old male who developed immediate bilateral retrobulbar pain, red eye, and vision loss 15 min after receiving the BNT162B2 [108]. Fundus exam revealed a hemorrhagic CRVO with ischemic areas on fluorescein angiography and OCT showed cystoid macular edema.…”

Section: Central and Hemi-retinal Vein Occlusionmentioning

confidence: 99%

Ocular Complications Following Vaccination for COVID-19: A One-Year Retrospective

et al. 2022

View full text Add to dashboard Cite

Vaccination efforts as a mitigation strategy in the corona virus disease 2019 (COVID-19) pandemic are fully underway. A vital component of understanding the optimal clinical use of these vaccines is a thorough investigation of adverse events following vaccination. To date, some limited reports and reviews have discussed ocular adverse events following COVID-19 vaccination, but a systematic review detailing these reports with manifestations and clinical courses as well as proposed mechanisms has yet to be published. This comprehensive review one-year into vaccination efforts against COVID-19 is meant to furnish sound understanding for ophthalmologists and primary care physicians based on the existing body of clinical data. We discuss manifestations categorized into one of the following: eyelid, orbit, uveitis, retina, vascular, neuro-ophthalmology, ocular motility disorders, and other.

show abstract

Section: Central and Hemi-retinal Vein Occlusionmentioning

confidence: 99%

Ocular Complications Following Vaccination for COVID-19: A One-Year Retrospective

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A 52-year-old male was diagnosed with CRVO 15 days after receiving the first dose of BNT162b2 vaccination [ 21 ]. A 50-year-old healthy patient felt immediate visual reduction in his left eye during the 15 min of mandatory surveillance after receiving his second dose of BNT162b2, and was revealed to have CRVO 20 days after the date of vaccination [ 22 ]. A 54-year-old female was referred to an ophthalmology clinic 8 days after her second dose of mRNA-1273, and was diagnosed with combined central retinal artery occlusion and CRVO.…”

Section: Discussionmentioning

confidence: 99%

“…This increases the need for ophthalmological studies on vaccine-related side-effects, where SARS-CoV-2 vaccination may become annual. Known intraocular side-effects include acute macular neuroretinopathy, central serous chorioretinopathy, reactivation of Vogt-Koyanagi-Harada disease, panuveitis, Descemet’s membrane endothelial keratoplasty (DMEK) graft rejection, retinal hemorrhage and vascular events including retinal arterial occlusion and retinal vein occlusion (RVO) [ 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 ]. Here, we present a unique case series of RVO, and age-related macular degeneration (AMD) exhibiting submacular hemorrhage, temporally related to administration of SARS-CoV-2 vaccines.…”

Section: Introductionmentioning

confidence: 99%

Retinal Hemorrhage after SARS-CoV-2 Vaccination

Park

Byun²,

Byeon

et al. 2021

JCM

View full text Add to dashboard Cite

To report retinal vein occlusion (RVO) and age-related macular degeneration (AMD)-related submacular hemorrhage developing after administration of SARS-CoV-2 vaccines, a single-center, retrospective observational case series was conducted. Clinical data including fundus photographs and optical coherence tomography (OCT) scans were reviewed. Twenty-three eyes of 21 patients were included with the median age at symptom presentation being 77 years (range: 51–85 years). Twelve eyes (52.2%) had submacular hemorrhage and 11 (47.8%) had RVO. Twelve patients (60.9%) had been vaccinated with the Pfizer vaccine (BNT162b2) and 8 with the AstraZeneca (ChAdOx1) vaccine. Sixteen patients (76.2%) experienced ocular disease exacerbation after the first vaccination and 4 (19.0%) after the second vaccination. The median visual acuity (logarithm of the minimal angle of resolution; logMAR) before symptom development was 0.76 (interquartile range: 0.27–1.23); the median logMAR at symptom presentation was 1.40 (interquartile range 0.52–1.70). The median time between vaccination and symptom exacerbation was 2.0 days (interquartile range: 1.0–3.0 days). Five patients (23.8%) underwent tests for hematological abnormalities, including the presence of anti-PF4 antibodies; all were negative. Further studies with larger patient group for evaluation of effect of SARS-CoV-2 vaccination on retinal hemorrhage are necessary.

show abstract

“…Bialasiewicz et al reported a case of central retinal vein occlusion post-vaccination in an otherwise previously healthy 50-year-old male patient [ 56 ]. During the 15-min surveillance period after receiving the second dose of BNT162b2, the patient developed retrobulbar pain, red eye and decreased vision in his left eye, which was eventually found to be caused by a central retinal vein occlusion.…”

Section: Covid-19 Vaccine-associated Ocular Inflammationmentioning

confidence: 99%

The Eye of the Storm: COVID-19 Vaccination and the Eye

Betzler

Ng³

et al. 2021

Ophthalmol Ther

View full text Add to dashboard Cite

The COVID-19 pandemic has galvanized the global response towards the development of new vaccines based on novel technologies at an unprecedented pace. Since the widespread implementation of vaccination campaigns, case reports on vaccines' systemic side effects, including ocular manifestations, have emerged. Since administered vaccines are generally not able to cause the disease in the recipient, or induce an immune response against the pathogen, we hypothesize that the development of ocular phenomena post-COVID-19 vaccination may occur via an immune response elicited by the vaccine. Of many, the most common ocular adverse events include facial nerve palsy, central venous sinus thrombosis and acute anterior uveitis. These COVID-19 vaccine-induced ocular (CVIO) adverse events could resemble the ocular findings in some of the COVID-19 patients. This review will provide a comprehensive overview of published ocular side effects potentially associated with COVID-19 vaccination and serve as a springboard for further research into CVIO adverse events.

show abstract

Central retinal vein occlusion occurring immediately after 2nd dose of mRNA SARS-CoV-2 vaccine

Cited by 49 publications

References 4 publications

Ocular Complications Following Vaccination for COVID-19: A One-Year Retrospective

Ocular Complications Following Vaccination for COVID-19: A One-Year Retrospective

Retinal Hemorrhage after SARS-CoV-2 Vaccination

The Eye of the Storm: COVID-19 Vaccination and the Eye

Contact Info

Product

Resources

About